Nothing Special   »   [go: up one dir, main page]

Alquraini et al., 2016 - Google Patents

The interaction of lubricin/proteoglycan-4 (PRG4) with toll-like receptor 2: an anti-inflammatory role of PRG4 in synovial fluids from patients with osteoarthritis

Alquraini et al., 2016

View PDF
Document ID
4182032785777982123
Author
Alquraini A
Garguilo S
Zhang L
Schmidt T
Jay G
Elsaid K
Publication year
Publication venue
Osteoarthritis and Cartilage

External Links

Snippet

Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and superficial zone chondrocytes. PRG4 has a homeostatic role in the joint and PRG4 intra-articular treatment was shown to retard the progression of cartilage …
Continue reading at www.oarsijournal.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
US20200360392A1 (en) Digallic acid for reduction of inflammatory cytokine activity
RU2477727C2 (en) αvβ3 SELECTIVE POLYPEPTIDE, METHOD FOR PREPARING IT, POLYNUCLEOTIDE CODING IT, COMPOSITION CONTAINING SAID PEPTIDE, AND METHOD FOR TREATING AND PREVENTING
JP2019504064A (en) Anti-pro / latent myostatin antibodies and methods of use thereof
UA118843C2 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2017367277B2 (en) Muscle performance improvement compounds
JP7438757B2 (en) Peptide modulators of the interaction of human C-peptide and human elastin receptors for therapeutic applications
Braga Emidio et al. Structure, function, and therapeutic potential of the trefoil factor family in the gastrointestinal tract
Naidu et al. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines
PT2403605E (en) Compositions comprising an ap2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance
MX2013000804A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders.
JP2008500285A (en) Prouroguanylin, and synthetic analogs or proteolytic cleavage products derived therefrom, as therapeutic and diagnostic agents for diseases associated with salt homeostasis and / or water homeostasis
JP2009502790A (en) CFTR LPA2 receptor agonist inhibitor
He et al. A novel plant-produced asialo-rhuEPO protects brain from ischemic damage without erythropoietic action
Hong et al. Role of the calcium sensing receptor in cardiomyocyte apoptosis via mitochondrial dynamics in compensatory hypertrophied myocardium of spontaneously hypertensive rat
Song et al. Inhibitors of endopeptidase and angiotensin-converting enzyme lead to an amplification of the morphological changes and an upregulation of the substance P system in a muscle overuse model
Tenti et al. The emerging role of bradykinin in the pathogenesis of osteoarthritis and its possible clinical implications
US8357659B2 (en) Method of treating pain or itching with APETx2 peptide toxin
Alquraini et al. The interaction of lubricin/proteoglycan-4 (PRG4) with toll-like receptor 2: an anti-inflammatory role of PRG4 in synovial fluids from patients with osteoarthritis
IL131950A (en) Laminin peptides for the treatment of systemic lupus erythematosus
PT1701978E (en) Use of soluble t-cadherin for the treatment of metabolic disorders
US20180333455A1 (en) A method for modulating insulin-independent glucose transport using teneurin c-terminal associated peptide (tcap)
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
US20090023637A1 (en) Methods for detecting and treating interstitial cystitis
KR20150106492A (en) Composition for treating insulin resistance-related disease comprising substance capable of activating FPR2
Mohammadi Role of oxidized phospholipids in inflammatory pain